Pancreatic Cancer
Advertisement
Dr. Cleary discusses DDR deficiencies in metastatic pancreatic cancer and reviews the use of PARP inhibitors.
Zenocutuzumab may serve as an effective treatment for NRG1 fusion-positive pancreatic cancer, with low-grade AEs.
Drs. Stephen Liu and Benjamin Weinberg continue their discussion on the safety of zenocutuzumab in NRG1 fusion+ PDAC.
Drs. Stephen Liu and Benjamin Weinberg elaborate on the prevalence of NRG1 gene fusions in PDAC.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Challenges in designing and conducting clinical trials for patients with metastatic pancreatic ductal cancer are discussed.
The efficacy and safety of MEK inhibitors are compared to chemotherapy and other targeted therapies.
The KRAS G12R mutation is analyzed against other alterations in pancreatic adenocarcinoma, and research findings are shared.
Dr. Strosberg focuses on how previous exposure to alkylating agents can influence tumor biology or immune response.
Dr. Pant shared updates on a phase 1b dose escalation trial of gemcitabine, nab-paclitaxel, and lixumistat.
Dr. Shirakawa highlighted the results of the NAPOLEON-2 trial, including how RWD compare to clinical trial findings.
Dr. Dotan shared the effects of baseline geriatric and QOL assessments on outcomes for older patients with pancreatic cancer.
Dr. Abdelrahim details the impact of UGT1A1*28 polymorphism on tolerability in patients with mPDAC in the NAPOLI 3 study.
Results of NIR-B trial sheds light on the clinical utility of niraparib in patients with BRCA-mutated GI cancers.
A novel auto-segmentation model and radiomics signature may help with preoperative clinical decision-making for GEP-NETs.
Data on growing pancreatic cancer cases in young Americans shows that some cases are misattributed as early endocrine cancer.
Dr. Joseph Cullen discusses the combination of vitamin C with gemcitabine and nab-paclitaxel for pancreatic cancer.
The survival rate benefit increased over time for patients treated with TTFields, with a 13% improvement in OS at 12 months.
A recent study compared first-line chemotherapy, as the standard of care for PDAC, with other treatment options.
Entinostat has been utilized in other solid tumors for its ability to induce the inhibition of cell proliferation.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.